2021 Revenues ($USD) : $6,816,860,000
2021 Revenues (foreign currencies) : €5,777,000,000
2021 R&D spend : $1,922,220,000
2021 Number of Employees : 8,561
Fiscal Year End : 12/31/2021
Leader : CEO Jean-Christophe Tellier

Founded nearly a century ago, UCB therapies reached more than 3.7 million patients in 2021. The company enjoyed robust financial growth, with revenue hitting €5.78 billion, increasing 10% in constant exchange rates. In 2021, the Brussels-based company won approval in the EU and Great Britain for Bimzelx (bimekizumab). It launched VIMPAT as an adjunctive therapy for idiopathic generalized epilepsy in Japan and Australia. In 2020, the company acquired Ra Pharma for $2.3 billion. That acquisition gave the company the potential self-injection therapy for myasthenia gravis. In early 2022, the company acquired Zogenix for close to $2 billion. UCB won a new FDA indication for the epilepsy drug fenfluramine, which is now also approved for Lennox-Gastaut syndrome (LGS), a rare type of severe epilepsy. —BB